Anlotinib combined with penpulimab in the treatment of advanced adult thoracic spinal osteosarcoma: a case report
Abstract
Background: Spinal osteosarcoma is a rare and prognostically poor subtype of osteosarcoma, with limited efficacy from traditional chemoradiotherapy. The potential of targeted therapy combined with immunotherapy requires further exploration.
Case summary: A 53-year-old female with stage IV thoracic spinal osteosarcoma initially received intensity-modulated radiotherapy (total dose of 45 Gy in 15 fractions) and AP chemotherapy (doxorubicin 60 mg/m2 + cisplatin 100 mg/m2). Treatment was discontinued due to grade 4 myelosuppression and sepsis. Subsequently, concurrent combination therapy with anlotinib (12 mg daily for 14 days followed by a 7-day rest) and penpulimab (200 mg intravenously every 3 weeks) was initiated. Penpulimab was administered regularly for 2 years before discontinuation, while anlotinib was reduced to 10 mg daily due to grade 2 hand-foot syndrome and continued thereafter. Post-treatment, the patient achieved significant pain relief, restored self-care capacity, and stable disease (SD) with a progression-free survival (PFS) exceeding 33 months.
Lessons: This case demonstrates that sequential molecular targeted therapy and immunotherapy following chemoradiation can yield remarkable clinical outcomes, offering a novel therapeutic option for advanced spinal osteosarcoma. However, interindividual variations in treatment response underscore the need for future research to identify predictive biomarkers for patient stratification.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Artificial Intelligence in Medicine: Cross-Sectional Study Among Medical Students on Application, Education, and Ethical Aspects
- Information quality of videos related to esophageal cancer on tiktok, kwai, and bilibili: a cross-sectional study
- The quality and reliability of short videos about hypertension on TikTok: a cross-sectional study
- Quality and reliability evaluation of pancreatic cancer-related video content on social short video platforms: a cross-sectional study
- Quality and reliability of pediatric pneumonia related short videos on mainstream platforms: cross-sectional study
- Association between metabolic score for insulin resistance (METS-IR) and hypertension: a cross-sectional study based on NHANES 2007–2018
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.